Study of FP-1039 in Subjects With Endometrial Cancers

NCT ID: NCT01244438

Last Updated: 2021-12-13

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE2
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-01-31
• Study Completion Date: 2012-12-31

Brief Summary

An open-label, non-randomized, single arm study to assess the safety, tolerability, and pharmacokinetics of FP-1039 given by weekly intravenous (IV) administrations in advanced endometrial cancer patients with FGFR2-specific mutations. FP-1039 will be dosed weekly starting at a dose of up to 16 mg/kg.

Detailed Description

FP-1039 will be administered intravenously over 30 minutes once a week. All enrolled subjects will be monitored for the occurrence of unacceptable toxicity. Subjects with no evidence of disease progression or unacceptable toxicity after 4 doses of FP-1039 may continue to receive weekly treatment provided there continues to be no evidence of disease progression or unacceptable toxicity. Dosing will be discontinued if a subject has evidence of disease progression. Disease will be assessed approximately every 2 months.

Conditions

Endometrial Cancers With FGFR2 Mutations

Keywords

endometrial cancer; FGFR2 mutations

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

FP-1039

FP-1039

Group Type: EXPERIMENTAL

FP-1039

Intervention Type: DRUG

FP-1039 will be administered at a dose up to 16 mg/kg intravenously over 30 minutes once a week.

Interventions

FP-1039

FP-1039 will be administered at a dose up to 16 mg/kg intravenously over 30 minutes once a week.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Evidence of histologically or cytologically proven metastatic or locally advanced unresectable endometrial cancer bearing either the S252W or the P243R FGFR2 mutation.

2. Female at least 18 years of age

3. Performance status ≤ 1 on the ECOG Performance Status Scale

4. Adequate cardiac function e.g., NYHA Class I or II

5. Estimated life expectancy of at least 16 weeks

6. Measurable or evaluable disease by physical or radiologic examination

7. Must have recovered from the adverse effects of prior therapy at the time of enrollment to ≤ Grade 1 (excluding alopecia)

8. Meets laboratory criteria as specified per protocol.

Exclusion Criteria

1. Prior treatment with an inhibitor of the FGF/FGFR pathway

2. Prior treatment with any of the following:

• Cytotoxic chemotherapy (including investigational cytotoxic agents) or biologic agents (antibodies, immune modulators, cytokines) within 4 weeks, or nitrosoureas or mitomycin C within 6 weeks prior to the scheduled first dose of FP-1039
• A small-molecule kinase inhibitor (including investigational small-molecule kinase inhibitors) within 14 days (or 5 half lives of the drug or active metabolites) of the scheduled first dose of FP-1039
• Any other investigational therapy within 28 days of the first scheduled dose of FP-1039 Note: Any eligibility questions related to prior therapies including the timing from prior therapies should be discussed and a decision agreed on by the Investigator and the Sponsor in writing prior to the subject entering the study

3. Known hypersensitivity to the components of FP-1039

4. Current anticoagulation with therapeutic doses of warfarin (low-dose warfarin ≤ 1mg/day is permitted)

5. PT/INR and/or PTT test results at screening that are above 1.3 x the laboratory ULN.

6. No exclusionary medical history as described per the protocol.

7. Presence of any of the following conditions:

• Luminal intestinal cancers and/or abdominal carcinomatosis
• History of abdominal fistula, gastrointestinal perforation, peptic ulcer disease, or intra-abdominal abscess within 6 months prior to study enrollment
• Other potential risk factors for gastrointestinal perforation (i.e., acute diverticulitis, intra-abdominal abscess, gastrointestinal obstruction)

8. History of organ, bone marrow, or stem cell transplantation

9. Pregnant or breast feeding

10. Clinically apparent CNS metastases or carcinomatous meningitis Note: Subjects with CNS metastases who have completed a course of radiotherapy and who have been on a stable dose of glucocorticoids for at least 4 weeks are eligible.

11. Uncontrolled intercurrent illness including but not limited to an active infection, hypertension, psychiatric, or substance abuse disorders that would preclude consent, limit compliance with study requirements, or confound safety interpretation.

12. Unable or unwilling to abide by the study protocol or cooperate fully with the Investigator or designee

• Minimum Eligible Age: 18 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Worldwide Clinical Trials

OTHER

Sponsor Role: collaborator

Five Prime Therapeutics, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Harold Keer, MD, PhD

Role: STUDY_CHAIR

Five Prime Therapeutics, Inc.

Countries

Russia; Serbia; Ukraine; United States

Other Identifiers

2010-024344-15

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

FP1039-002

Identifier Type: -

Identifier Source: org_study_id